27697674|t|Levels of the soluble LDL receptor-relative LR11 decrease in overweight individuals with type 2 diabetes upon diet-induced weight loss
27697674|a|Cardiovascular disease (CVD) is a major complication in patients with type 2 diabetes (T2D), especially in those with obesity. Plasma soluble low density lipoprotein receptor-relative with 11 ligand-binding repeats (sLR11) plays a role in the development of atherosclerosis and has been linked to the metabolism of triglyceride-rich lipoproteins, adiposity, and vascular complications in T2D. We aimed to determine the effect of diet-induced weight loss on plasma sLR11 levels in overweight and obese individuals with T2D. Plasma sLR11 levels were determined in 64 individuals with T2D and BMI >27 kg/m(2) before and after a 20- week weight loss diet. As a reference, sLR11 levels were also determined in 64 healthy, non-obese controls, matched as a group for age and sex. Median plasma sLR11 levels of the T2D study-group at baseline (15.4 ng/mL (IQR 12.9-19.5)) were higher than in controls (10.2 (IQR: 8.7-12.2) ng/mL; p = 0.001). The diet resulted in a weight loss of 9.7 Â± 5.2% (p = 0.001) and improved CVD risk factors. sLR11 levels were reduced to 13.3 ng/mL (IQR 11.0-17.1; p = 0.001). Changes in sLR11 levels positively associated with changes in non-HDL cholesterol (B = 1.54, R(2) = 0.17, p = 0.001) and HbA1c (B = 0.07, R(2) = 0.11, p = 0.007), but not with weight loss (B = 0.04, R(2) = 0.05, p = 0.076). The changes in non-HDL cholesterol and HbA1c together explained 24% of the variance of sLR11 reduction (p = 0.001). Weight loss dieting in overweight and obese individuals with T2D resulted in a reduction in plasma sLR11 levels that was associated with improvements in lipid-profile and glycemic state.
27697674	14	21	soluble	T080	C1948047
27697674	22	48	LDL receptor-relative LR11	T116,T192	C1307867
27697674	49	57	decrease	T081	C0547047
27697674	61	83	overweight individuals	T098	C3825277
27697674	89	104	type 2 diabetes	T047	C0011860
27697674	110	134	diet-induced weight loss	T184	C2169615
27697674	135	157	Cardiovascular disease	T047	C0007222
27697674	159	162	CVD	T047	C0007222
27697674	175	187	complication	T046	C0009566
27697674	191	199	patients	T101	C0030705
27697674	205	220	type 2 diabetes	T047	C0011860
27697674	222	225	T2D	T047	C0011860
27697674	253	260	obesity	T047	C0028754
27697674	262	268	Plasma	T031	C0032105
27697674	269	276	soluble	T080	C1948047
27697674	277	349	low density lipoprotein receptor-relative with 11 ligand-binding repeats	T116,T192	C1307867
27697674	351	356	sLR11	T116,T192	C1307867
27697674	393	408	atherosclerosis	T047	C0004153
27697674	436	446	metabolism	T040	C0025519
27697674	450	480	triglyceride-rich lipoproteins	T116,T123	C0023820
27697674	482	491	adiposity	T032	C1563743
27697674	497	519	vascular complications	T047	C1393529
27697674	523	526	T2D	T047	C0011860
27697674	564	588	diet-induced weight loss	T184	C2169615
27697674	592	598	plasma	T031	C0032105
27697674	599	604	sLR11	T116,T192	C1307867
27697674	605	611	levels	T080	C0441889
27697674	615	625	overweight	T098	C3825277
27697674	630	635	obese	T047	C0028754
27697674	636	647	individuals	T098	C0237401
27697674	653	656	T2D	T047	C0011860
27697674	658	664	Plasma	T031	C0032105
27697674	665	670	sLR11	T116,T192	C1307867
27697674	671	677	levels	T080	C0441889
27697674	700	711	individuals	T098	C0237401
27697674	717	720	T2D	T047	C0011860
27697674	725	728	BMI	T201	C1305855
27697674	764	768	week	T079	C0439230
27697674	769	785	weight loss diet	T061	C0012167
27697674	803	808	sLR11	T116,T192	C1307867
27697674	809	815	levels	T080	C0441889
27697674	843	850	healthy	T080	C3898900
27697674	852	870	non-obese controls	T096	C0009932
27697674	885	890	group	T078	C0441833
27697674	895	898	age	T032	C0001779
27697674	903	906	sex	T032	C0079399
27697674	915	921	plasma	T031	C0032105
27697674	922	927	sLR11	T116,T192	C1307867
27697674	928	934	levels	T080	C0441889
27697674	942	945	T2D	T047	C0011860
27697674	946	957	study-group	T098	C2348561
27697674	961	969	baseline	T081	C1442488
27697674	1019	1027	controls	T096	C0009932
27697674	1073	1077	diet	T168	C0012155
27697674	1092	1103	weight loss	T033	C1262477
27697674	1143	1146	CVD	T047	C0007222
27697674	1147	1159	risk factors	T033	C0035648
27697674	1161	1166	sLR11	T116,T192	C1307867
27697674	1167	1173	levels	T080	C0441889
27697674	1240	1245	sLR11	T116,T192	C1307867
27697674	1246	1252	levels	T080	C0441889
27697674	1291	1310	non-HDL cholesterol	T109,T123	C0729627
27697674	1350	1355	HbA1c	T116,T123	C0019018
27697674	1405	1416	weight loss	T033	C1262477
27697674	1468	1487	non-HDL cholesterol	T109,T123	C0729627
27697674	1492	1497	HbA1c	T116,T123	C0019018
27697674	1540	1545	sLR11	T116,T192	C1307867
27697674	1546	1555	reduction	T081	C0547047
27697674	1569	1588	Weight loss dieting	T061	C0012167
27697674	1592	1602	overweight	T098	C3825277
27697674	1607	1612	obese	T047	C0028754
27697674	1613	1624	individuals	T080	C0205556
27697674	1630	1633	T2D	T047	C0011860
27697674	1648	1657	reduction	T081	C0547047
27697674	1661	1667	plasma	T031	C0032105
27697674	1668	1673	sLR11	T116,T192	C1307867
27697674	1674	1680	levels	T080	C0441889
27697674	1722	1735	lipid-profile	T059	C0200382
27697674	1740	1754	glycemic state	T081	C1136206